Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia

Pathology and Oncology Research

Volumn 19, Issue 1, 2013, Pages 119-122

  Rubovszky, Gábor ^a   Nagy, Tünde ^a   Gődény, Mária ^a   Szász, András ^b   Láng, István ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SZENT ISTVÁN UNIVERSITY   (Hungary)

Author keywords

Bevacizumab; Hyperthermia; Lung cancer; Solitary bone metastases

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ZOLEDRONIC ACID;

ADENOCARCINOMA; ADULT; ARTICLE; BONE METASTASIS; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; EGFR GENE; FINE NEEDLE ASPIRATION BIOPSY; GENERAL MEDICAL DEVICE; HUMAN; HUMAN TISSUE; HYPERTHERMIA; HYPERTHERMIC THERAPY; K RAS GENE; LOBECTOMY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; THORAX RADIOGRAPHY;

EID: 84873085158     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9551-7     Document Type: Article

References (25)

1. Wakelee HA, Bernardo P, Johnson DH et al (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 06:2208-2217
2. Yang P, Allen MS, Aubry MC et al (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 28:452-462
3. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544
4. Azzoli CG, Baker S, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for Stage IV non-Nmall-Cell Lung Cancer. J Clin Oncol 27:6251-6266
5. Sandler A, Gray R, Perry MC (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
6. Reck M, von Pawel J, Zatloukal P (2009) Phase iii trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 27:1227-1234
7. Laskin J, Crinò L, Tsai C (2009) MO19390 (SAIL): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (nsclc) - outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 4(Suppl 1):S359
8. Hirsh V (2008) Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clin Lung Cancer 9(suppl 2):S62-S70
9. Crinò L, Mezger J, Griesinger F et al (2009) MO19390 (SAIL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (nsclc) [abstract 8043] Proc Am Soc. Clin Oncol 27:417s
10. Fischbach N, Spigel D, Brahmer J, on behalf of the ARIES investigators (2009) Preliminary safety and effectiveness of bevacizumab (bv) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (nsclc) from the aries study: a bevacizumab (bv) treatment observational cohort study (ocs) [abstract 8040]. Proc Am Soc Clin Oncol 27:416s
11. Mezger J, von Pawel J, Reck M (2009) Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (nsclc): results from an exploratory analysis of the avail study [abstract e19001] Proc Am Soc. Clin Oncol 27:e19001
12. Miller V, O'Connor P, Soh C, on behalf of the ATLAS Investigators (2009) A randomized, double-blind, placebo-controlled, phase iiib trial (atlas) comparing bevacizumab (b) therapy with or without erlotinib (e) after completion of chemotherapy with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract LBA8002] Proc Am Soc. Clin Oncol 27:799s
13. Hildebrandt B, Wust P, Ahlers O et al (2002) The cellular and molecular basis of hyperthermia. Clin Rev Oncol Haemat 43:33-56
14. Jiang Z, Yan W, Ming J et al (2007) Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study. BMC Cancer 7:189
15. Shen H, Li XD, Wu CP et al (2011) The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study. Int J Hyperthermia 27:27-32
16. Mitsumori M, Zeng ZF, Oliynychenko P et al (2007) Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. Int J Clin Oncol 12:192-198
17. Moon SD, Ohguri T, Imada H et al (2011) Definitive radiotherapy plus regional hyperthermia with or without chemotherapy for superior sulcus tumors: a 20-year, single center experience. Lung Cancer 71:338-343
18. Sumiyoshi K, Strebel FR, Rowe RW et al (2003) The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia 19:103-118
19. Hermisson M, Weller M (2000) Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 20(3A):1819-1823
20. Szasz A, Szasz N, Szasz O (2010) Oncothermia -principles and practices. Springer Verlag, Heidelberg
21. Chun-Yi L, Yiing-Feng H, Hua-Tzu H et al (2009) Lung cancer with solitary bone metastasis in the radius. Clin Nucl Med 34:684-685
22. Shih WJ, Magoun S, Lahar B et al (1998) An unusual case of a tibial metastasis as the clinical presentation of bronchogenic adenocarcinoma. J Nucl Med Technol 26:91-93
23. An SJ, Huang YS, Chen ZH (2011) et al. Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy, Med Oncol [Epub ahead of print]
24. Horn L, Dahlberg SE, Sandler AB et al (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-6011
25. Herbst RS, Ansari R, Bustin F et al (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846-1854